The evidence suggests that CB2R activation is a therapeutic target for mitigating obesity-associated inflammation and excess lipid storage in white adipose tissue by modulating perilipin expression, upregulating IL-4, and stimulating UCP-1 signaling. Here, UCP1 is linked to obesity due to melanocortin 4 receptor deficiency.